Literature DB >> 17828302

Functionally distinct monomers and trimers produced by a viral oncoprotein.

S-H Chung1, R S Weiss, K K Frese, B V V Prasad, R T Javier.   

Abstract

While the process of homo-oligomer formation and disassembly into subunits represents a common strategy to regulate protein activity, reports of proteins in which the subunit and homo-oligomer perform independent functions are scarce. Tumorigenesis induced by the adenovirus E4-ORF1 oncoprotein depends on its binding to a select group of cellular PDZ proteins, including MUPP1, MAGI-1, ZO-2 and Dlg1. We report here that in cells E4-ORF1 exists as both a monomer and trimer and that monomers specifically bind and sequester MUPP1, MAGI-1 and ZO-2 within insoluble complexes whereas trimers specifically bind Dlg1 and promote its translocation to the plasma membrane. This work exposes a novel strategy wherein the oligomerization state of a protein not only determines the capacity to bind separate related targets but also couples the interactions to different functional consequences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828302      PMCID: PMC3471668          DOI: 10.1038/sj.onc.1210784

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Actin dynamics control SRF activity by regulation of its coactivator MAL.

Authors:  Francesc Miralles; Guido Posern; Alexia-Ileana Zaromytidou; Richard Treisman
Journal:  Cell       Date:  2003-05-02       Impact factor: 41.582

2.  Pit-1 binding to specific DNA sites as a monomer or dimer determines gene-specific use of a tyrosine-dependent synergy domain.

Authors:  J M Holloway; D P Szeto; K M Scully; C K Glass; M G Rosenfeld
Journal:  Genes Dev       Date:  1995-08-15       Impact factor: 11.361

3.  Human adenovirus early region 4 open reading frame 1 genes encode growth-transforming proteins that may be distantly related to dUTP pyrophosphatase enzymes.

Authors:  R S Weiss; S S Lee; B V Prasad; R T Javier
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.

Authors:  T Kiyono; A Hiraiwa; M Fujita; Y Hayashi; T Akiyama; M Ishibashi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

5.  Staphylococcal alpha-toxin increases the permeability of lipid vesicles by cholesterol- and pH-dependent assembly of oligomeric channels.

Authors:  S Forti; G Menestrina
Journal:  Eur J Biochem       Date:  1989-05-15

6.  Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein.

Authors:  S S Lee; R S Weiss; R T Javier
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

7.  A transient three-plasmid expression system for the production of high titer retroviral vectors.

Authors:  Y Soneoka; P M Cannon; E E Ramsdale; J C Griffiths; G Romano; S M Kingsman; A J Kingsman
Journal:  Nucleic Acids Res       Date:  1995-02-25       Impact factor: 16.971

8.  Staphylococcal alpha-toxin: oligomerization of hydrophilic monomers to form amphiphilic hexamers induced through contact with deoxycholate detergent micelles.

Authors:  S Bhakdi; R Füssle; J Tranum-Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

9.  Human dUTP pyrophosphatase: uracil recognition by a beta hairpin and active sites formed by three separate subunits.

Authors:  C D Mol; J M Harris; E M McIntosh; J A Tainer
Journal:  Structure       Date:  1996-09-15       Impact factor: 5.006

10.  PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein augments the transforming activity in a rat fibroblast cell line.

Authors:  Akira Hirata; Masaya Higuchi; Akiko Niinuma; Minako Ohashi; Masaya Fukushi; Masayasu Oie; Tetsu Akiyama; Yuetsu Tanaka; Fumitake Gejyo; Masahiro Fujii
Journal:  Virology       Date:  2004-01-05       Impact factor: 3.616

View more
  8 in total

Review 1.  Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses.

Authors:  Ronald T Javier; Andrew P Rice
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

2.  Hijacking Dlg1 for oncogenic phosphatidylinositol 3-kinase activation in human epithelial cells is a conserved mechanism of human adenovirus E4-ORF1 proteins.

Authors:  Manish Kumar; Kathleen Kong; Ronald T Javier
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

3.  The ESEV PDZ-binding motif of the avian influenza A virus NS1 protein protects infected cells from apoptosis by directly targeting Scribble.

Authors:  Hongbing Liu; Lisa Golebiewski; Eugene C Dow; Robert M Krug; Ronald T Javier; Andrew P Rice
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

4.  E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus.

Authors:  Michael A Thomas; Robin S Broughton; Felicia D Goodrum; David A Ornelles
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

5.  Adenovirus E4-ORF1 Dysregulates Epidermal Growth Factor and Insulin/Insulin-Like Growth Factor Receptors To Mediate Constitutive Myc Expression.

Authors:  Kathleen Kong; Manish Kumar; Midori Taruishi; Ronald T Javier
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

Review 6.  Cell polarity proteins: common targets for tumorigenic human viruses.

Authors:  R T Javier
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

7.  The human adenovirus E4-ORF1 protein subverts discs large 1 to mediate membrane recruitment and dysregulation of phosphatidylinositol 3-kinase.

Authors:  Kathleen Kong; Manish Kumar; Midori Taruishi; Ronald T Javier
Journal:  PLoS Pathog       Date:  2014-05-01       Impact factor: 6.823

Review 8.  Upsetting the Balance: When Viruses Manipulate Cell Polarity Control.

Authors:  Miranda Thomas; Lawrence Banks
Journal:  J Mol Biol       Date:  2018-04-20       Impact factor: 5.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.